The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

FRIDAY, Sept. 6, 2024 -- Gene therapy may restore vision to children and adults robbed of their sight by a rare inherited condition called Leber...

Using a novel stem cell platform, a team of the Medical University of South Carolina researchers has identified a pathway that could be targeted by...

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Therefore, the selection of engineered capsids that demonstrate desirable properties is critical to making informed decisions for AAV-based gene...

Competitive: Cytel - EMEA: Sr. Clinical Programmer   Join Cytel’s enthusiastic and collaborative Biometrics team by contributing to the overall...

The World Health Organization said Friday it has granted its first authorization for use of a vaccine against mpox in adults, calling it an important...